SEC Form 4 · accession 0001213900-17-001708
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis M Brown
Officer — Chief Scientific Officer · Director
Period of report
Feb 17, 2017
Accepted (ET)
Feb 22, 2017 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options (Right to Buy)F1 | $4.95 | Feb 17, 2017 | A | 93,600 | A | Feb 17, 2020 | Feb 17, 2027 | Common Stock | 93,600 | 93,600 | D |
Explanation of responses
- F1The options vest in equal monthly installments over three years.